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Interleukin- (IL-) 17 is important in the development of asthma and host defense against pneumococci. We determined the role of
IL-17 in the risk of pneumococcal pneumonia. We challenged mice intranasally with a bioluminescent Streptococcus pneumoniae
strain after sensitization and challenge with ovalbumin (OVA). We measured the levels of cytokines, including IL-17 (pg/mL),
in the lung homogenate in experimental mice with and without OVA sensitization/challenge, as well as those with and without
pneumococcal pneumonia. IL-17 levels were signiﬁcantly lower in OVA-sensitized/challenged mice (9.69 ± 1.49), compared to the
control mice (20.92 ± 1.82, P<0.001). In our overall analysis, including IL-4 and IL-17 levels and OVA sensitization/challenge,
IL-4 levels (OR: 81.9, 95%CI: 4.3–1523 per increment of 1.0pg/mL, P = 0.003) were more signiﬁcant than IL-17 levels (OR: 1.1,
95%CI: 1.03–1.17 per increment of 1.0pg/mL, P = 0.003) in determining the risk of pneumococcal pneumonia. IL-17 levels result
in a much smaller impact on the risk for pneumococcal pneumonia, compared to IL-4 levels.
1.Introduction
Streptococcuspneumoniaeisaleadingcauseofbacterialpneu-
monia, meningitis, and sepsis and has caused substantial
morbidity and mortality in the United States and worldwide,
especially in young children. Recent estimates of childhood
deaths caused by Streptococcus pneumoniae range from
70,000 to 1 million every year worldwide, and S. pneumoniae
caused around 11% of all deaths in children aged 1–59
months [1]. In 2000, about 14.5 million episodes of serious
pneumococcal disease were estimated to occur, and pneu-
mococcal disease caused about 826,000 deaths in children
aged 1–59 months [1]. In the US, 40,000 cases of fatal
pneumococcal infections per year have been reported [2].
Recently some studies reported that individuals with asthma
have a signiﬁcantly increased risk of invasive pneumococcal
disease, compared to those without asthma [3, 4]. Thus,
the Advisory Committee on Immunization Practices has
a recommendation for the use of 23-valent pneumococcal
polysaccharide vaccine (PPV23) for the prevention of inva-
sive pneumococcal disease in asthmatics [5]. At present, little
is known about the mechanisms underlying the increased
risk of invasive pneumococcal disease among individuals
with asthma. We previously reported that a T-helper 2
(Th2) predominant immune response (e.g., IL-4) to OVA
sensitization was a signiﬁcant risk factor for pneumococcal2 International Journal of Microbiology
infection, whereas allergic sensitization itself was protective
against pneumococcal pneumonia [6]. Others also reported
thatIL-4wasassociatedwithdiminishedhostdefenseagainst
Pseudomonas lung infection in mice [7]. Therefore, while
Th2cytokinessuchasIL-4areassociatedwithariskofbacte-
rial pneumonia in mice, how allergic sensitization provides a
protective eﬀect against pneumococcal pneumonia in mice is
not well understood. One potential hypothesis is that allergic
sensitization-induced IL-17 may provide a protective eﬀect
against pneumococcal disease because IL-17 is a cytokine
that enhances host defense against pneumococcal infection.
T-helper 17 (Th17) cells are a newly discovered CD4+
helper T-cell subset that produce IL-17 and are involved
in host defense against bacterial infection, mainly through
the recruitment and activation of neutrophils [8]. IL-17 is
an important inﬂammatory mediator in the development
of asthma [9, 10] and protection from pneumococcal colo-
nization [11, 12]. Indeed, recent studies report that allergic
sensitization with OVA in mice induced secretion of IL-17
from macrophages and elevation of IL-17 levels in BAL ﬂuid
[10, 13], but production of IL-17 by Th17 cells (particularly
IL-23-dependent IL-17 secretion) was negatively regulated
by IL-4 [14]. Therefore, we hypothesize that elevated IL-17
levels in BAL induced by allergic sensitization may provide
ap r o t e c t i v ee ﬀect on the development of pneumococcal
pneumonia. To test this hypothesis, we investigated the role
of IL-17 in both airway inﬂammation and pneumococcal
pneumonia using a murine model.
2.MaterialsandMethods
2.1. Experiment. Experimental details have been previously
reported [6] the study was approved by the Mayo Clinic
IACUC. Brieﬂy, pathogen-free 6–8-week-old female BALB/c
mice were sensitized by intraperitoneal (i.p.) injection of
20μgO V Aa d s o r b e dt o1 m ga l u m i n u mh y d r o x i d eg e l( i n
a volume of 100μL) on days 0 and 7. Then, experimental
mice were intranasally challenged with 100μgO V Ai n
50μL phosphate-buﬀered saline (PBS) under light tribro-
moethanol anesthesia on days 15, 16, and 17. Control mice
received i.p. injection of PBS with aluminum hydroxide gel
but no intranasal challenge. Three days after OVA challenge,
the OVA-sensitized/challenged mice and control mice were
challenged with S. pneumoniae A 66.1 serotype 3 (1.5 × 104
to 3 × 104 cfu), made bioluminescent by integration of a
modiﬁed lux operon into its chromosome (Xen 10, Caliper
Life Sciences, Hopkinton, Mass, USA) [15]. Pneumococcal
pneumonia was deﬁned as the presence of bioluminescence
and positive pneumococcal culture from normally sterile
body tissues (spleen or brain). Cytokine and chemokine
levels in the lung tissues were determined by Bio-Plex or
ELISA assays.
2.2. Outcome Measures and Statistical Analysis. To examine
the impact of OVA sensitization/challenge on IL-17 levels
in the lung, we compared IL-17 levels between OVA-
sensitized/challenged and control mice after stratiﬁcation
into mice that developed pneumococcal pneumonia and
those that did not. To assess the role of IL17 in the risk of
pneumococcal disease, we compared IL-17 levels between
mice with and without pneumococcal pneumonia and
determined the correlation between IL-17 levels and colony
counts of pneumococci from lung and spleen (log10 CFU)
using Pearson’s correlation coeﬃcient. To determine the
relationship between IL-4 and IL-17, we calculated Pearson’s
correlation coeﬃcient between IL-17 and Th2 cytokines.
To examine whether the impact of IL-17 on pneumococ-
cal infection is independent of sensitization and challenge
with OVA and IL-4, data were ﬁtted to a logistic regression.
We calculated odds ratios (ORs) and corresponding 95%
conﬁdence intervals for OVA sensitization/challenge, IL-17
levels, IL-4 levels, and the interaction term between OVA
sensitization/challenge and IL-4 to identify factors associated
with the risk of pneumococcal pneumonia. All statistical
signiﬁcance was tested at a two-tailed alpha error of 0.05.
3. Results
3.1. Relationship between IL-17 Levels in Lung, OVA Sensiti-
zation/Challenge, and Pneumococcal Pneumonia. IL-17 levels
were signiﬁcantly lower in OVA-sensitized/challenged mice,
compared to the control mice (9.69 ± 1.49 versus 20.92 ±
1.82pg/mL, P<0.001) and were elevated in mice with com-
pared to those without pneumococcal pneumonia (20.53 ±
1.96 versus 10.28 ± 1.44pg/mL, P<0.001).
The results stratiﬁed by pneumococcal pneumonia status
are summarized in Table 1. IL-17 level was lower in OVA-
sensitized/challenged mice, compared to control mice in
the mice without pneumococcal pneumonia (P = 0.001).
However, there was no diﬀerence in IL-17 levels between
OVA-sensitized/challenged mice and control mice in mice
with pneumococcal pneumonia (P = 0.13). In OVA-
sensitized/challengedmice,theIL-17levelwashigherinmice
that developed pneumococcal pneumonia than those that
did not (P = 0.01). However, in the control mice, the IL-
17 level was not associated with pneumococcal pneumonia
(P = 0.21).
IL-17 levels were positively correlated with pneumo-
coccal colony counts in the lung and spleen in the mice
with OVA sensitization/challenge, but not the control mice
(Figures 1 and 2).
3.2. Correlation between IL-17 Levels and Other Cytokines and
Chemokines in Lung. IL-17 levels were positively correlated
with IL-1α (r = 0.31), IL-13 (0.32), and RANTES (r =0.37)
levels in the lungs of sensitized mice (P<0.05), whereas
IL-17 levels were inversely correlated with IL-4 levels in
the lungs of mice without pneumococcal pneumonia, a
ﬁnding which approached statistical signiﬁcance (r =−0.29,
P =0.05). There was no correlation between IL-17 and other
cytokines (IL-1, IL-2, IL-5, IL-6, IL-10, IFN-γ,a n dT N F - α)
or chemokines (GM-CSF, EOTAXIN, and MIP-1) in lung
homogenates.
3.3. Factors Associated with the Risk of Pneumococcal Pneu-
monia. The results on the inﬂuence of IL-17, IL-4, and OVAInternational Journal of Microbiology 3
Table 1: Comparison of IL-17 among the OVA-sensitized/challenged mice and the control mice stratiﬁed by pneumococcal pneumonia
status.
OVA-sensitized/challenged mice Control mice P value
Mice with pneumococcal pneumonia 15.94 ± 2.92 22.5 ± 2.44 0.13
Mice without pneumococcal pneumonia 7.43 ± 1.59 17.52 ± 2.12 0.001
P value 0.01 0.21
Data are presented as mean ± standard error (pg/mL). The lung tissues of mice at the time of death or pneumococcal pneumonia or those of mice
without pneumococcal pneumonia at day 7 wer eh o m o g e n i z e dw i t h2m Lo fP B Sa n df r o z e na t−20◦C for subsequent cytokine analysis. IL-17 levels in lung
homogenates were determined by ELISA methods.
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Figure 1: Correlation between IL17 levels in lung homogenates and pneumococcal colony counts in lung. To assess the eﬀect of IL-17 on
the risk of pneumococcal pneumonia, the correlation between IL-17 levels in the lung and pneumococcal colony count in the lung was
examined. When mice developed pneumococcal pneumonia by bioluminescence or expired, we measured IL-17 levels and pneumococcal
colony counts in the lung. As shown in the ﬁgure, IL-17 levels in the lung were positively correlated with pneumococcal colony counts in
lungs of mice with OVA sensitization/challenge (r = 0.32, P = 0.033), but not the controls. OVA sensitization/challenge modiﬁed the eﬀect
of IL-17 on the risk of pneumococcal pneumonia. log CFU; log10 colony forming units of pneumococci.
sensitization/challenge on the risk of pneumococcal pneu-
monia are summarized in Table 2. The mean level (±
standard error) of IL-4 in lung homogenates among mice
with pneumococcal pneumonia was 1.09 ± 0.14pg/mL
whereasthatamongmicewithoutpneumococcalpneumonia
was 0.67 ± 0.06pg/mL (P =0.0037). Therefore, adjusting for
the impact of IL-4 and OVA sensitization/challenge on the
risk on pneumococcal pneumonia, IL-17 minimally inﬂu-
enced the risk of pneumococcal pneumonia. OVA sensiti-
zation/challenge was not signiﬁcantly associated with the
risk of pneumococcal pneumonia, but, as we previously
reported, IL-4 was still signiﬁcantly associated with the risk
of pneumococcal pneumonia adjusting for IL-17 and OVA
sensitization/challenge.
4. Discussion
In our study, sensitization/challenge with OVA reduced the
risk of pneumococcal pneumonia (28% versus 57%) and
the number of pneumococci in the lung homogenates of
mice with pneumococcal pneumonia, compared to control
mice. This reduced risk of pneumococcal pneumonia in
OVA-sensitized/challenged mice was minimally accounted
for by IL-17 levels in lung, but IL-4 levels in lung were
more signiﬁcantly associated with the risk of pneumococcal
pneumonia than IL-17.
Our results suggest that IL-17 levels were lower in OVA-
sensitized/challenged mice than the control mice, particu-
larly in mice without pneumococcal pneumonia. However,4 International Journal of Microbiology
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Figure 2: Correlation between IL17 levels in lung homogenates and pneumococcal colony counts in spleen. To assess the eﬀe c to fI L - 1 7
on the risk of invasive pneumococcal disease instead of pneumococcal pneumonia, the correlation between IL-17 levels in the lung and
pneumococcal colony count in the spleen, which should be sterile normally, was assessed. When mice developed invasive pneumococcal
disease involving the spleen (by bioluminescence) or expired, we measured IL-17 levels and pneumococcal colony counts in the lung. There
was a signiﬁcant correlation between IL-17 levels in the lung homogenate and pneumococcal colony counts in the spleen among the OVA-
sensitized/challenged mice (r = 0.36, P = 0.014), but no signiﬁcant correlation was found in the control mice. OVA sensitization/challenge
modiﬁed the eﬀect of IL-17 on the risk of invasive pneumococcal disease. ∗log CFU: lo4g10 colony forming units of pneumococci.
Table 2: Logistic regression models assessing the impact of each variable on the risk of pneumococcal pneumonia.
Variables Odds ratios (95%CI)∗ P value
IL-17 (per an increment of 1.0pg/mL) 1.10 (1.03–1.17) 0.003
OVA sensitization/challenge 4.03 (0.46–35.07) 0.21
IL-4 (per an increment of 1.0pg/mL) 81.9 (4.30–1523.87) 0.003
The logistic regression model was adjusted for the interaction term between IL-4 and OVA sensitization/challenge.
it is uncertain whether OVA sensitization/challenge failed
to induce IL-17 since we did not have a baseline measure
of IL-17. However, Th2 cytokines showed an inconsistent
relationship with IL-17 levels. There was no correlation
between IL-5 and IL-17 levels. IL-4 was inversely correlated
withIL-17levelswhereasIL-13waspositivelycorrelatedwith
IL-17 levels in the lung. Therefore, in our mouse model,
allergic sensitization might not signiﬁcantly increase IL-17
levels in the lung homogenate but the inconsistent eﬀects of
Th2 cytokines on IL-17 levels. Previous studies reported that
OVA sensitization/challenge increases IL-17 levels in lung [9,
10]. However, Schnyder-Candrian et al. reported that IL-17
has a dual role: it is essential during antigen sensitization to
establish allergic asthma, but, in sensitized mice, IL-17 atten-
uates the allergic response by inhibiting chemokines [10]. In
our study, IL-17 levels in the lung were positively correlated
with IL-1 levels but inversely correlated with IL-4 levels,
ﬁndings which are consistent with the literature [14, 16–18].
For the relationship between IL-17 levels in the lung
and the risk of pneumococcal pneumonia, in our study,
IL-17 levels in the lung were associated with an increased
risk of pneumococcal pneumonia, particularly in OVA-
sensitized/challenged mice. IL-17 levels in the lung are
positively correlated with pneumococcal colony counts from
lung and spleen as summarized in Figures 1 and 2,a n d
there was a positive association between IL-17 levels and
pneumococcal pneumonia as summarized in Tables 1 and 2.
In interpreting these results, IL-17 levels in the lung might
reﬂect host response to pneumococcal pneumonia (i.e., IL-
17 levels induced by pneumococcal pneumonia) instead
of causing an increased risk of pneumococcal pneumonia.
However, we observed increased IL-17 levels in mice with
pneumococcal pneumonia only among the group of OVA-
sensitized/challenged mice, but IL-17 levels did not diﬀer
between mice with and without pneumococcal pneumonia
in the control mice as shown in Table 1. Also, IL-17 levelsInternational Journal of Microbiology 5
were not correlated with pneumococcal colony counts in
lung and spleen in the control mice. Therefore, IL-17 levels
in the lung might not solely reﬂect the host response to
pneumococcal pneumonia. The role of IL-17 in host defense
from microbial infections including pneumococcal infection
has been well supported by the literature [11, 12, 19, 20]. IL-
17 participates in host defense through regulation of innate
immunity (e.g., recruitment of neutrophils and induction of
antimicrobial peptides) and cell-mediated immunity (e.g.,
T-cell activation) [8, 20]. However, our study results were
in contrast with these studies and suggest a potential
adverse eﬀect of IL-17 on host defense. Our study is limited
in addressing this unexpected ﬁnding, and we can only
speculate as to the potential explanation. As an organism-
speciﬁc mechanism, a recent study reported that IL-17 up-
regulates expression of polymeric immunoglobulin receptor
(PIgR) by epithelial cells, a receptor for pneumococcal
cholin-binding protein A (CbpA) [21]. CbpA has been
known as an important pneumococcal adhesin to certain
receptors (e.g., PIgR as well as platelet-activating factor
receptor) to invade through reverse epithelial transcytosis
[22, 23]. Thus, upregulation of PIgR may increase binding
of pneumococci to the epithelial cell surface and allow
pneumococci to invade epithelial cells and inner tissues,
resulting in serious infections [24]. Also, Th2 cytokines such
as IL-4 upregulate PIgR and may further enhance invasion
of pneumococci in the presence of IL-17 which may account
forthepositivecorrelationbetweenIL-17andpneumococcal
colony count in the lung and spleen only among OVA-sen-
sitized/challenged but not control mice, as observed in our
study [22]. As a nonspeciﬁc mechanism for the negative
inﬂuence of IL-17 on the risk of pneumococcal pneumonia,
IL-17 has been reported to promote inﬂammation by induc-
ing various proinﬂammatory cytokines and chemokines,
recruiting neutrophils, enhancing antibody production, and
activating T cells [24]. The etiologic involvement of IL-
17 in certain autoimmune conditions such as rheumatoid
arthritis [25] and multiple sclerosis [26]h a sb e e ns u g g e s t e d .
Therefore, IL-17 might result in signiﬁcant airway inﬂam-
mation damaging lung architecture and making the host
susceptible to microbial infections. Indeed, previous studies
showed that IL-17 was associated with increased risks of
Aspergillus fumigatus infection and diminished antifungal
immunity [27]. However, in our study, the overall impact of
IL-17 on the risk of pneumococcal pneumonia was minimal
(OR: 1.10), taking into account the role of IL-4 and OVA
sensitization/challenge as summarized in Table 2.
As we previously reported, IL-4 levels in the lung were
still a signiﬁcant factor for the risk of pneumococcal pneu-
monia in our mouse model, adjusting for the role of IL-
17 and OVA sensitization/challenge. The adverse eﬀect of
IL-4 on the risk of microbial infections has been well
supported by the literature [28, 29]. Thus, as discussed
above, given the dual eﬀects (protective and provocative)
of IL-17 on the risk of pneumococcal pneumonia, IL-4
(and attenuated production of proinﬂammatory cytokines
by reciprocal inhibition by Th2 cytokines) may play a more
important role in determining the risk of pneumococcal
pneu-monia than IL-17.
The main strengths of our study were a large sample
size of mice ensuring suﬃcient statistical power and use of
a luminescence technique allowing us to identify pneumo-
coccal pneumonia without sacriﬁcing mice. Our study also
had limitations. There was no measurement for IL-17 levels
in the lung at baseline (time zero), and IL-17 levels were
measured at diﬀerent time points depending on disease
progress of mice, which may inﬂuence the interpretation of
the results. Another limitation of the animal model of this
study was acute airway inﬂammation status, and the result
might not be applicable for asthma in human, a chronic air-
way inﬂammation.
In conclusion, our study results highlight that allergic
sensitization may not induce IL-17, and IL-17 levels in
the lung may result in a negative inﬂuence on host defense
against pneumococcal pneumonia, albeit minimal. However,
IL-4 levels in the lung are still more important for deter-
mining the risk of pneumococcal pneumonia than IL-17
and allergic sensitization. Given the limitations of our study,
further studies are needed to clarify the role of IL-17 in the
risk of pneumococcal disease.
Abbreviations
OR: Odds ratio
95%CI: 95% conﬁdence interval
CFU: Colony forming unit
OVA: Ovalbumin.
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